Trial Profile
A multicenter, double-blind, placebo-controlled, randomized trial of the drug Runihol in patients with non-alcoholic fatty liver disease in the presence of metabolic syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Inosine (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors POLYSAN
- 06 Feb 2019 Status changed from recruiting to discontinued.
- 16 Jan 2018 Planned End Date changed from 1 Nov 2017 to 1 Nov 2020.
- 16 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2020.